Synergy Constipation Drug Begins Phase III
By Catherine Shaffer
Wednesday, November 13, 2013
Synergy Pharmaceuticals Inc. launched the first of two Phase III trials of its investigational drug for chronic idiopathic constipation, plecanatide. The 12-week trial will enroll about 1,350 patients with an endpoint of overall response.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.